Veloxis Pharma Inc. v. Alkem Laboratories Ltd.

This patent infringement litigation, Veloxis Pharma Inc. v. Alkem Laboratories Ltd., arises from an Abbreviated New Drug Application (ANDA) filing. The plaintiff, Veloxis Pharma Inc., is a fully integrated specialty pharmaceutical company focused on improving the lives of transplant patients, known for its proprietary MeltDose® drug formulation technology. Veloxis is an Asahi Kasei company. The defendant, Alkem Laboratories Ltd., is an Indian multinational pharmaceutical operating company specializing in developing, manufacturing, and selling pharmaceutical and nutraceutical products, including generic drugs, with a significant global presence.

The accused product is Alkem's generic version of Veloxis's branded immunosuppressant, ENVARSUS XR® (tacrolimus), specifically 0.75 mg, 1 mg, and 4 mg extended-release tablets of tacrolimus, for which Alkem submitted ANDA No. 219575 to the FDA. ENVARSUS XR® is a calcineurin-inhibitor immunosuppressant primarily used to prevent organ rejection in transplant patients, particularly kidney transplant recipients. The primary patent at issue, US Patent No. 11,419,823, titled "Stabilized tacrolimus composition," generally covers a stable pharmaceutical composition of tacrolimus that includes a stabilizing agent to prevent or reduce the formation of degradation products, such as 8-epitacrolimus, during storage.

This Hatch-Waxman litigation was filed on July 3, 2024, in the U.S. District Court for the District of Delaware under case number 1:24-cv-00784. Judge Maryellen Noreika presided over the case. The District of Delaware is a common venue for ANDA cases, historically handling a large percentage of such filings nationwide, largely due to the high number of pharmaceutical companies incorporated in the state and the court's extensive experience with complex drug patent disputes. The case concluded relatively quickly, closing on January 13, 2026, with a consent judgment and a permanent injunction entered against Alkem Laboratories Ltd., preventing them from manufacturing, selling, or importing their generic tacrolimus product (ANDA No. 219575) until the expiration of Veloxis's asserted patents. This outcome indicates a successful defense of Veloxis's intellectual property rights and reinforces its market exclusivity for ENVARSUS XR®.

This patent infringement litigation, Veloxis Pharma Inc. v. Alkem Laboratories Ltd., Case No. 1:24-cv-00784, was filed in the U.S. District Court for the District of Delaware and concluded with a consent judgment. The case involved U.S. Patent No. 11,419,823, among others, relating to Veloxis's ENVARSUS XR® (tacrolimus) product.

Here is a chronological overview of the key legal developments and outcome:

• Filing & Initial Pleadings (2024-07-03): Veloxis Pharma Inc. filed a complaint for patent infringement against Alkem Laboratories Ltd. in the U.S. District Court for the District of Delaware. The lawsuit alleged infringement of multiple U.S. patents, including 8,685,998; 9,549,918; 10,166,190; 10,864,199; 11,110,081; 11,123,331; and 11,419,823, based on Alkem's submission of Abbreviated New Drug Application (ANDA) No. 219575 seeking approval to market generic extended-release tacrolimus tablets. Alkem's answer to the complaint admitted to providing Veloxis with a Notice of Paragraph IV Certification for these patents.

• Claim Construction (Markman) (2025-10-20): A Markman hearing, for claim construction, was held before Judge Maryellen Noreika.

• Discovery Milestones (2026-01-13): A Stipulation and Order to Extend Certain Deadlines in the Scheduling Order was signed by Judge Maryellen Noreika, setting deadlines for rebuttal expert reports (January 20, 2026), reply expert reports (February 5, 2026), and expert discovery (February 27, 2026).

• Final Disposition (2026-01-13): The case was terminated by a Consent Judgment signed by Judge Maryellen Noreika. While the specific terms are typically confidential, consent judgments in ANDA cases often reflect a settlement, potentially including a licensing agreement that allows for generic market entry at a specified future date.

• Parallel PTAB IPR/PGR Proceedings: Based on available public information, no parallel inter partes review (IPR) or post-grant review (PGR) proceedings were identified for U.S. Patent No. 11,419,823 before the Patent Trial and Appeal Board (PTAB) related to this specific litigation.

In the patent infringement case of Veloxis Pharma Inc. v. Alkem Laboratories Ltd. (1:24-cv-00784) in the U.S. District Court for the District of Delaware, Veloxis Pharma Inc. is consistently represented by:

• Firm: Morris, Nichols, Arsht & Tunnell LLP
• Office Location: Wilmington, Delaware

While specific docket entries detailing the appearance of individual attorneys for this exact case (1:24-cv-00784) were not directly available in the provided search results, Morris, Nichols, Arsht & Tunnell LLP is a pre-eminent intellectual property litigation firm in Delaware, frequently representing Veloxis Pharma Inc. in Abbreviated New Drug Application (ANDA) patent infringement cases in the District of Delaware. Based on their established pattern of representation for Veloxis in similar D. Del. ANDA matters, the following attorneys from the firm are highly likely to have been involved:

• Name: Jeremy A. Tigan

  • Role: Partner (likely lead or local counsel)
  • Firm: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE
  • Experience: An experienced IP litigation partner, Jeremy Tigan focuses on patent infringement and trade secret disputes, often acting as lead or Delaware counsel for pharmaceutical clients in the District of Delaware, with experience in bench and jury trials and appeals before the Third and Federal Circuits. He served as the head of the firm's IP litigation practice group from 2020-2024.

• Name: Jennifer Ying

  • Role: Partner (likely local counsel)
  • Firm: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE
  • Experience: An intellectual property litigator, Jennifer Ying focuses on patent, trademark, and trade secret disputes in federal and state court, including Hatch-Waxman patent infringement actions for pharmaceutical clients. She has a technical background in electrical engineering & computer science and has been recognized as a leading patent litigator.

Despite multiple searches for the counsel of record for Alkem Laboratories Ltd. in Veloxis Pharma Inc. v. Alkem Laboratories Ltd., case number 1:24-cv-00784, in the U.S. District Court for the District of Delaware, specific attorney names and their firms could not be definitively identified through publicly available web search results.

While the docket for this closed case refers to "Attorneys for Defendant Alkem Laboratories. Ltd." in Document 12, filed on October 17, 2024, and mentions a "Certificate of Service" dated October 7, 2024, the names of the individual attorneys and their associated law firms were not explicitly extracted or provided in the available search snippets. Therefore, information regarding their specific roles (e.g., lead counsel, local counsel) and relevant patent litigation experience is also not available for this case.